← Volver a la portada
Estados Unidos · Plataformas y datos · Yahoo Finance

Ellipses Pharma plots London listing that could end British biotech IPO drought

Publicado por Yahoo Finance · Estados Unidos hace 9 h
Ellipses Pharma plots London listing that could end British biotech IPO drought
Yahoo Finance

Resumen detallado

"Ellipses Pharma plots London listing that could end British biotech IPO drought" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

London-based Ellipses Pharma said it might conduct an initial public offering (IPO) on home soil, an announcement that could mark the end for one of the longest ever dry spells for biotech listings in Britain.

Ellipses, which is developing treatments for various types of cancer, said it has signed an agreement in principle with special purpose acquisition company (SPAC) Wolfram Resources.

Ellipses and Wolfram are targeting a deal completion by early 2027, though caveated that there is no guarantee the proposed transaction will proceed.

SPACs are already listed shell companies that acquire private companies to take them public on the stock market. This method used to be considerably more common five years ago given their higher safety, though fell out of fashion after many companies with speculative growth trajectories failed to reach valuations.

With a low enthusiasm for listings on the London Stock Exchange (LSE) this year, Ellipses has so far decided to go down the SPAC route. The biotech's non-binding Memorandum of Understanding with Wolfram will see a reverse takeover, with the latter acquiring Ellipses' whole share capital.

There has not been a single biotech that listed on the LSE in 2026, marking one of the quietest windows in the sector's history in the capital. Experts have also highlighted the challenging investment climate across the wider European capital markets scene.

In stark contrast, the US IPO scene has exploded in 2026. There have been around 30 biotech and pharma listings on the New York Stock Exchange (NYSE) and the Nasdaq, marking the strongest year since the 2020/2021 boom.

Targeting a listing on home soil marks a positive step for the UK biotech sector, which has seen numerous funding and exit successes this year. This week, Isomorphic Labs raised $5bn in the largest ever biotech Series C round.

Professor Sir Chris Evans, Ellipses CEO, said: "Our company has been focused resolutely on the development of promising drug candidates and the progress…

Inicio del artículo, extracto de Yahoo Finance. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

También te puede interesar